



Real-time neuroimaging for anyone, anywhere

Valentina Lidoni - Co-founder & CEO

February 2026

Imaging is fundamental to clinical diagnosis

Yet it remains largely confined to hospital-based radiology.

As a result, access to imaging outside traditional hospital settings remains limited, often delaying clinical decisions and restricting diagnostic insight.

Imaging is fundamental to clinical diagnosis

Yet it remains largely confined to hospital-based radiology.

As a result, access to imaging outside traditional hospital settings remains limited, often delaying clinical decisions and restricting diagnostic insight.

In **neurology**, timing defines outcomes

Neurological conditions evolve rapidly and require immediate clinical decisions.

Yet **70%** of suspected stroke patients do not receive neuroimaging within the therapeutic window, limiting timely intervention and impacting recovery.

Cost of Stroke

**US\$
890
Billion
2017**



**US\$
1.6
Trillion
2050**

Solution

Rilemo extends access to neuroimaging beyond traditional hospital settings, enabling earlier, faster and more informed clinical decisions.



Portable

Imaging available directly at the point of decision

Safe

Non-ionizing technology enabling early and repeatable imaging

Real-time

Actionable brain images delivered in seconds

Technology

Rilemo's proprietary technology is built on years of research, combining microwave imaging and AI.

Microwave Imaging Core

A circumferential antenna array emits and receives low-power microwave signals, capturing dielectric contrasts associated with pathological brain conditions

Technology

Rilemo's proprietary technology is built on years of research, combining microwave imaging and AI.

Microwave Imaging Core

A circumferential antenna array emits and receives low-power microwave signals, capturing dielectric contrasts associated with pathological brain conditions

Advanced Signal Processing

Proprietary algorithms process raw microwave signals, compensating for noise, geometry and tissue variability to reconstruct medical data volumes

Technology

Rilemo's proprietary technology is built on years of research, combining microwave imaging and AI.

Microwave Imaging Core

A circumferential antenna array emits and receives low-power microwave signals, capturing dielectric contrasts associated with pathological brain conditions

Advanced Signal Processing

Proprietary algorithms process raw microwave signals, compensating for noise, geometry and tissue variability to reconstruct medical data volumes

AI Engine

A structured AI pipeline translates reconstructed data into actionable outputs in real-time

Intellectual Property

Rilemo has built a structured and evolving IP strategy combining patents, proprietary know-how and trade secrets to protect and scale its technology over time.

Hardware

1 Patent Granted in
IT+EU & USA on tech

+2 Patents Pending
on device family

Positive FTO and prior art search

Additional filings in
preparation

Software

Proprietary
algorithms & AI

Developed fully
in-house

Built on
proprietary data


Brand

**1 Registered
Trademark**
(EU+UK)

Under international
extension

Technology Validation

A fully functional prototype has been validated in a clinically relevant environment, demonstrating accurate detection and localization of the target pathology and reaching TRL 6.



Validation was conducted with clinicians using anatomical phantoms to simulate realistic neurological conditions.

Differentiation

Rilemo enables rapid, bedside and pre-hospital imaging, expanding access to critical information beyond the constraints of conventional imaging systems.

	 Rilemo	MRI	CT	Ultrasound
				
Time to diagnosis	< 1 sec	15-30 min	5-10 min	< 2 min
Portability	Yes	No	No	Yes, with limitations
Versatility	Yes	Yes	Yes	Can't penetrate bones
Invasiveness	No	Undressing, no contact	Undressing, no contact	Undressing, pressure

Rilemo's technology is complementary to traditional techniques, not a replacement.

Market Positioning & Expansion

Powered by patented technology, Rilemo strategically unlocks multiple clinical applications, focusing first on high-need settings with agile regulatory pathways, and building toward a scalable, multi-product portfolio.

Neuroimaging

Bedside

Emergency Department
Intensive Care Units
Neurology
Neurosurgery

First Line

Emergency Department
Ambulances
Helicopters (HEMS)
Territorial Care

Clinical Expansion

Lungs
Breast
Bone and joints

+HOME CARE


Enabling neurological imaging directly at home

+RSA

Bringing rapid neuroimaging to fragile and chronic patients

Market Sizing

The market sizing reflects Rilemo's first neuroimaging device, addressing hospitals, emergency services and long-term care settings reachable under the current regulatory framework.



Market estimates derived from a bottom-up analysis.

Team

Rilemo is driven by a multidisciplinary team spanning medical devices, AI, clinical practice and healthcare operations.



Valentina Lidoni

Co-founder & CEO



Nadim Conti

Co-founder, CTO &
Chairman



Pablo Giaccaglia

Co-founder & CIO



Alessia Rosa

Co-founder & Chief
Medical Officer



Desiree Spreafico

Co-founder & CCO



Diego Bonato

Software Engineer



Raffaele Biondi

Hardware Engineer



Valentina Mara

Biomedical Engineer



Niccolò Puccia

Software Scientist



Davide Mauri

Sensors Engineer



Nura Conti

UX & Interaction
Design

Key Advisors & Partners

Rilemo is supported by a strong advisory and partner network, contributing to the de-risking of its path to market.



Luca Sconfienza
Clinical



Michela Pantaleoni
Pricing & Market
Access



Enrico Perfler
Regulatory



Claudio Prete
Sales



Fabrizio Bellina
Go-to-market



Piermaria Sartor
Finance



UNIVERSITÀ
DEGLI STUDI
DI MILANO



Product Roadmap


The product roadmap defines the value-creation journey from industrialization to market entry and scale.

First Production Batch

First batch of final devices manufactured through a qualified contract manufacturer.

Clinical Investigation Completed

Pivotal clinical study supporting CE marking under the Medical Device Regulation.



Industrialization Kickoff

Transition from prototype to industrial-grade device, including design for manufacturing and supply chain setup.

Final Pre-Clinical Validation & First-in-Human

Final cadaver-based validation and first-in-human studies to confirm safety and performance.

CE Marking & Market Entry

CE marking obtained and commercial launch in the European market.

Funding Ask

The present Seed round positions Rilemo for regulatory clearance, market entry and initial revenue generation.



€ 3M

Clinical Investigation & CE Marking


Completion of the clinical investigation and achievement of CE marking, enabling commercial deployment across European hospitals.

Commercial Team Structuring

Building the initial commercial team to drive hospital adoption and support early market access.

Device Production & Market Launch

Manufacturing of commercial devices and launch of initial go-to-market activities with priority customers.



Rilemo

Diagnose Anyone, Anywhere